Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

ClinicalTrials.gov ID: NCT02367040

Public ClinicalTrials.gov record NCT02367040. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free interval of ≥ 12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.

Study identification

NCT ID: NCT02367040
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 458 participants

Conditions and interventions

Conditions

Lymphoma,Non-Hodgkin

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 2, 2015
Primary completion: Aug 30, 2020
Completion: Nov 14, 2024
Last update posted: Oct 13, 2025

2015 – 2024

United States locations

U.S. sites: 16
U.S. states: 9
U.S. cities: 13

Facility	City	State	ZIP	Site status
Not listed	West Covina	California	91790	—
Not listed	Ashland	Kentucky	41101	—
Not listed	Louisville	Kentucky	40207	—
Not listed	Bethesda	Maryland	20817	—
Not listed	Las Vegas	Nevada	89169	—
Not listed	Montvale	New Jersey	07645	—
MSK Basking Ridge	New Jersey	New Jersey	—	—
MSK Bergen	New Jersey	New Jersey	—	—
MSK Monmoth	New Jersey	New Jersey	—	—
MSK Westchester	Harrison	New York	—	—
MSK Commack	Long Island City	New York	—	—
MSK Rockville Centre	Long Island City	New York	—	—
Not listed	New York	New York	10065	—
Not listed	Canton	Ohio	44718	—
Not listed	Salt Lake City	Utah	84106	—
Not listed	Spokane	Washington	99208	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 171 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02367040, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 13, 2025 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02367040 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →